<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05112952</url>
  </required_header>
  <id_info>
    <org_study_id>CR109022</org_study_id>
    <secondary_id>2021-001950-71</secondary_id>
    <secondary_id>73841937NSC1007</secondary_id>
    <nct_id>NCT05112952</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effect of Hepatic Impairment on Lazertinib (JNJ-73841937)</brief_title>
  <official_title>A Single-Dose, Open-Label, Parallel-Group, Multi-Center Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Lazertinib (JNJ-73841937)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the pharmacokinetics (PK) of a single oral dose of&#xD;
      lazertinib in participants with impaired hepatic function when compared with healthy&#xD;
      participants with normal hepatic function, under fed conditions.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 16, 2021</start_date>
  <completion_date type="Anticipated">December 22, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 22, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma Concentrations of Lazertinib</measure>
    <time_frame>Predose up to 312 hour postdose (up to Day 14)</time_frame>
    <description>Plasma concentrations of lazertinib will be analyzed using a validated, specific, and sensitive method to assess the effect of hepatic impairment on the pharmacokinetic of lazertinib.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability</measure>
    <time_frame>Up to 49 days</time_frame>
    <description>AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Hepatic Impairment</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Part A: Group 1: Moderate Hepatic Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with moderate hepatic impairment will receive a single oral dose of lazertinib.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Group 2: Normal Hepatic Function</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants with normal hepatic function who qualify for the control group will receive a single oral dose of lazertinib.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Group 3 (Optional): Mild Hepatic Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with mild hepatic impairment will receive a single oral dose of lazertinib.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Group 4 (Optional): Severe Hepatic Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with severe hepatic impairment will receive a single oral dose of lazertinib.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lazertinib</intervention_name>
    <description>Lazertinib tablet will be administered orally.</description>
    <arm_group_label>Part A: Group 1: Moderate Hepatic Impairment</arm_group_label>
    <arm_group_label>Part A: Group 2: Normal Hepatic Function</arm_group_label>
    <arm_group_label>Part B: Group 3 (Optional): Mild Hepatic Impairment</arm_group_label>
    <arm_group_label>Part B: Group 4 (Optional): Severe Hepatic Impairment</arm_group_label>
    <other_name>JNJ-73841937,</other_name>
    <other_name>YH25448</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        All Participants:&#xD;
&#xD;
          -  Must have a clinically stable hepatic function as confirmed by the serum bilirubin and&#xD;
             transaminase levels measured during screening and those measured on Day -1&#xD;
&#xD;
          -  Willing and able to adhere to the prohibitions and restrictions specified in this&#xD;
             protocol&#xD;
&#xD;
          -  If a woman, must not be of childbearing potential: postmenopausal (amenorrhea for at&#xD;
             least 12 months and a serum follicle stimulating hormone within postmenopausal range);&#xD;
             or surgically sterile (hysterectomy, bilateral salpingectomy, bilateral oophorectomy,&#xD;
             bilateral tubal occlusion/ligation procedure)&#xD;
&#xD;
        Healthy Participants with normal hepatic function:&#xD;
&#xD;
          -  Blood pressure (after the participant is supine for 5 minutes) between 90 and 140&#xD;
             millimeter of mercury (mmHg) systolic for participants less than or equal to (&lt;=) 60&#xD;
             years old and between 90 and 150 mmHg for participants greater than (&gt;) 60 years old,&#xD;
             inclusive, and no higher than 90 mmHg diastolic. If blood pressure is out of range, up&#xD;
             to 2 repeated assessments are permitted per visit&#xD;
&#xD;
          -  Pharmacogenomics: Healthy participants must have matching glutathione S-transferase Mu&#xD;
             1 (GSTM1) genotype (null or non-null GSTM1 genotype) to individual hepatic impairment&#xD;
             group participants&#xD;
&#xD;
        Participants with hepatic impairment:&#xD;
&#xD;
          -  A 12-lead electrocardiogram (ECG) consistent with adequate cardiac conduction and&#xD;
             function as per judgement by the investigator, including: a) Sinus rhythm; b) Heart&#xD;
             rate between 50 and 100 beats per minute (extremes included); c) QTc interval &lt;= 480&#xD;
             milliseconds (ms) (corrected cf. Fridericia; QTcF)&#xD;
&#xD;
          -  Concomitant medications to treat underlying disease states or medical conditions&#xD;
             related to hepatic impairment are allowed. Participants must be on a stable dose of&#xD;
             medication and/or treatment regimen for at least 2 weeks before dosing as well as&#xD;
             during the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        All Participants:&#xD;
&#xD;
          -  Participant has known allergies, hypersensitivity, or intolerance to Lazertinib or its&#xD;
             excipients&#xD;
&#xD;
          -  Any surgical or medical condition that may alter the absorption, metabolism, or&#xD;
             excretion of the study drug (example, gastrectomy, Crohn's disease etc.), with the&#xD;
             exception of hepatic impairment&#xD;
&#xD;
          -  Active gall bladder or biliary tract disease (example, acute cholecystitis,&#xD;
             symptomatic cholelithiasis)&#xD;
&#xD;
          -  Participant tests positive for human immunodeficiency virus (HIV)-1 or HIV-2 at&#xD;
             screening&#xD;
&#xD;
          -  Participant has a lack of adequate venous access&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Contact</last_name>
    <phone>844-434-4210</phone>
    <email>JNJ.CT@sylogent.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>CRS Clinical Research Services Kiel GmbH</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APEX GmbH</name>
      <address>
        <city>Munchen</city>
        <zip>81241</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 2, 2021</study_first_submitted>
  <study_first_submitted_qc>November 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2021</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lazertinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data sharing policy of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu</ipd_description>
    <ipd_url>https://www.janssen.com/clinical-trials/transparency</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

